Skip to content

study on anemia with two different drugs (itrifal fauladi and majoon khabsul hadeed)

A comprative evaluation of itrifal fauladi with majoon khabsul hadeed in the management of su-al-qinya (iron deficiency anemia): An open label randomized clinical trial. - nill

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/081365
Enrollment
60
Registered
2025-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Itrifal Fauladi: 7 gm OD for 60 days orally after meal with normal water Control Intervention1: Control Drug: Majoon khabsul hadeed: 05 gm OD for 60 days orally after meal with normal w

Sponsors

Govt Tibbi College And Hospital Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. patient having hemoglobin between 7gm/dl to 12gm/dl. 2. MCV less than 80fl 3. MCH less than 26pg 4. MCHC less than 31gm/dl 5. Serum ferratin less than 10mcg 6. Patient suffering from Microcytic hypochromic anaemia on Blood Peripheral smear/

Exclusion criteria

Exclusion criteria: 1) Patients not willing to sign the consent form. 2) Patient below the age of 18 years and above the age of 65 years. 3) Pregnant and lactating women. 4) Patient already taking treatment for anemia. 5) Patients suffering from malignancy, Hypertension, Diabetes mellitus. 6) Patients with any bleeding history e.g., Abnormal uterine bleeding, piles/rectal bleeding, haemoptysis and hematemesis etc. 7) Patients with chronic renal failure. 8) Patients with chronic liver disease. 9) Patients suffering from thalassemia /sickle cell disease and any other haemolytic disorders. 10) Patients taking blood thinners or any other drug which causes haemolysis.

Design outcomes

Primary

MeasureTime frame
1.Haemoglobin 2.Peripheral blood smear 3.Serum ferritin Timepoint: at baseline, 30 days, and 60 days

Secondary

MeasureTime frame
1. Pallor. 2. Fatigue. 3. Dyspnoea. 4. Giddiness. 5. Anorexia Timepoint: at baseline, 30 days, and 60 days

Countries

India

Contacts

Public ContactDr Md Razi Ahmad

Govt. Tibbi. College And Hospital Patna

drmdnajibur.rahman@gmail.com9122332101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026